Table of Contents<\/b><\/p>\n [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=”7093″ img_size=”full”][vc_column_text single_style=””]Figure 1. DNA Damage Spectrum: From Classical Lesions to Folate-Linked Vulnerabilities. <\/b>Illustration of major DNA lesions affecting genomic integrity, including (1)<\/b> base mismatches<\/i><\/u> arising from replication errors, (2)<\/b> single-stranded breaks<\/i><\/u> caused by oxidative stress or repair intermediates, (3)<\/b> double-stranded breaks<\/i><\/u> resulting from replication fork collapse or enzymatic cleavage, (4)<\/b> interstrand cross-links<\/i> that obstruct strand separation during replication, and (5)<\/b> bulky adducts or intrastrand crosslinks<\/i><\/u> induced by environmental mutagens or metabolic byproducts. Folate deficiency or impaired one-carbon metabolism<\/span> can contribute to each of these damage types through distinct biochemical pathways: (A)<\/b> Base mismatch<\/b>: Elevated UTP\/TTP ratio<\/b> leads to uracil misincorporation in place of thymidine, resulting in frequent base mismatches and repair stress. (B) Single-stranded breaks<\/b>: Excision of uracil by base excision repair enzymes creates abasic sites and transient single-strand breaks, especially in rapidly dividing cells. (C)<\/b> Double-stranded breaks<\/b>: Closely spaced uracil lesions on opposite strands or failed repair of single-strand breaks can culminate in double-strand breaks, particularly within tumor suppressor loci (<\/b>Apc<\/i><\/b>, <\/b>p53<\/i><\/b>)<\/b>. (D)<\/b> Interstrand cross-links<\/b>: Folate-related methylation defects may impair repair pathways (e.g., Fanconi anemia pathway), increasing susceptibility to cross-linking agents. (E)<\/b> Bulky adducts\/intrastrand crosslinks<\/b>: Aberrant methylation patterns and impaired detoxification may enhance vulnerability to endogenous or exogenous adduct formation, compounding genomic instability. These aberrations underscore folate\u2019s role as a genomic gatekeeper<\/span>\u2014where deficiency, excess, or dysregulation can tip the balance from repair to rupture, with implications for both cancer risk and therapeutic safety<\/span>.[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_id=”introduction”][vc_column][vc_custom_heading text=”Introduction”][vc_column_text single_style=”” el_id=”blog-scroll-point-1″]Folate, a cornerstone of one-carbon metabolism, has long been celebrated for its indispensable role in DNA synthesis<\/b>, repair<\/b>, and methylation<\/b>\u2014processes that safeguard genomic integrity and regulate gene expression. As a dietary micronutrient and therapeutic agent, folate occupies a unique position at the intersection of nutritional biochemistry<\/b>, developmental biology<\/b>, and cancer prevention<\/b>. Yet, as our understanding deepens, so too does the complexity of its narrative.<\/p>\n Over the past two decades, a robust body of epidemiological, clinical, and mechanistic evidence<\/b> has converged to support the notion that adequate folate status reduces the risk of several cancers<\/b>, most notably those of the colorectum<\/b>, breast<\/b>, and pancreas<\/b>. The biological rationale is compelling: folate deficiency disrupts<\/i> nucleotide balance, promotes uracil misincorporation, impairs DNA repair, and alters methylation patterns<\/i><\/span>\u2014each a potential trigger for malignant transformation. However, this protective paradigm is now tempered by a growing recognition of folate\u2019s context-dependent duality<\/b>.<\/p>\n In individuals with pre-existing neoplastic lesions<\/b>, high-dose folate<\/span>\u2014particularly in the form of folic acid or folinic acid<\/b>\u2014may paradoxically accelerate tumor progression<\/b> by fueling the proliferative demands of dysplastic cells. This phenomenon, once viewed as paradoxical, is now understood as a predictable consequence of folate\u2019s biochemical potency. It is within this nuanced framework that public health recommendations<\/b>, clinical interventions<\/b>, and precision nutrition strategies<\/b> must be re-evaluated.<\/p>\n Nowhere is this tension more palpable than in the autism community<\/b>, where high-dose folinic acid<\/b><\/span> is increasingly used to support neurodevelopmental outcomes<\/b> in children with cerebral folate deficiency<\/b> or mitochondrial dysfunction<\/b>. While many families report meaningful improvements, a lingering concern<\/b> persists: could prolonged exposure to supraphysiologic folate levels\u2014especially in genetically or metabolically vulnerable children<\/u><\/span>\u2014carry unintended oncogenic risks<\/b>? Although definitive answers remain elusive, the question underscores the urgent need for longitudinal safety data<\/b>, biomarker surveillance<\/b>, and a mechanistic understanding<\/b> of how folate modulates cellular fate across developmental and disease contexts.<\/p>\n This article synthesizes the current landscape of folate and carcinogenesis, with a focus on the molecular mechanisms<\/b>, genomic vulnerabilities<\/b>, and nutrient-gene interactions<\/b> that shape cancer risk. In doing so, it aims to inform a more nuanced, evidence-based dialogue<\/b>\u2014one that honors both the promise and the complexity<\/b> of folate in human health.[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_id=”blog-scroll-point-1″][vc_column][vc_custom_heading text=”Folate and Carcinogenesis: A Dual-Edged Metabolic Sword” use_theme_fonts=”yes”][vc_column_text single_style=””]A substantial and steadily expanding body of preclinical and clinical evidence<\/b>, particularly in the context of colorectal neoplasia<\/b>, supports a protective role for folate<\/b> in cancer prevention. This protective association is also emerging\u2014albeit with less consistency\u2014for malignancies of the breast, lung, pancreas, and esophagus<\/b>. However, this narrative is complicated by a paradoxical observation<\/b>: when folate is consumed in excessive amounts<\/b>, especially in individuals who already harbor precancerous or malignant lesions<\/b>, it may accelerate tumor progression<\/b> rather than prevent it.<\/p>\n What initially appears to be a contradiction is, in fact, biologically coherent<\/b> when viewed through the lens of folate\u2019s cellular functions. This \u201cdual effect\u201d hypothesis<\/b>\u2014where folate may either suppress or promote carcinogenesis depending on timing and cellular context\u2014poses a significant challenge for public health policy<\/b>, as it implies that population-wide recommendations<\/b> may not be universally beneficial. Thus, any mechanistic framework aiming to explain folate\u2019s role in cancer risk must grapple with this bidirectional potential<\/b>.<\/p>\n [\/vc_column_text][\/vc_column][\/vc_row][vc_row el_id=”blog-scroll-point-2″][vc_column][vc_custom_heading text=”Mechanistic Pathways and Modifying Factors in Folate-Driven Tumor Biology” use_theme_fonts=”yes”][vc_column_text single_style=””]<\/p>\n At the molecular level, folate\u2019s sole established biochemical role<\/b> is its function as a cofactor and substrate in one-carbon (1C) metabolism<\/b>\u2014a network of reactions that transfers single-carbon units between molecules. Through this role, folate is indispensable for both biological methylation<\/b> and the de novo synthesis of purines and thymidylate<\/b>, which are essential for DNA replication and repair<\/b>.<\/p>\n The integrity of DNA synthesis, repair, and methylation<\/b>\u2014all of which are tightly folate-dependent\u2014is critical for maintaining genomic stability. Disruptions in these processes are well-recognized hallmarks of malignant transformation<\/b>. Consequently, folate deficiency<\/b> is theorized to promote carcinogenesis by fostering uracil misincorporation<\/b>, DNA strand breaks<\/b>, and global hypomethylation<\/b>, all of which can lead to oncogene activation<\/b> or tumor suppressor gene silencing<\/b> (see Figure 1<\/b>) [1-2].<\/p>\n Conversely, in rapidly proliferating neoplastic cells<\/b>, which have elevated demands for nucleotide synthesis<\/b>, excess folate<\/b> may inadvertently fuel tumor growth<\/b>\u2014particularly when administered after neoplastic transformation has already begun. This paradox underscores the importance of timing, dosage, and cellular context<\/b> in determining folate\u2019s net effect on cancer risk.<\/p>\n Adding further complexity, several modifying factors<\/b> influence folate\u2019s impact on carcinogenesis. These include:<\/p>\n The biochemical interdependence<\/b> of these nutrients is well-established, and their collective influence on methylation and nucleotide synthesis is increasingly recognized as clinically significant<\/b>. Notably, population-based surveys<\/b> reveal that subclinical deficiencies<\/b>\u2014nutrient levels below optimal but not low enough to cause overt deficiency syndromes\u2014are surprisingly prevalent<\/b> in adults across industrialized nations. This is particularly true for vitamins B\u2086 and B\u2081\u2082<\/b>, whose inadequacies have been linked in multiple studies to elevated cancer risk<\/b>.<\/p>\n [\/vc_column_text][vc_single_image image=”7095″ img_size=”full”][vc_column_text single_style=””]Figure 2. Cytosolic One-Carbon Metabolism: Folate-Driven Interconversions and Methylation Pathways. <\/b>Schematic representation of one-carbon metabolism<\/i><\/u><\/span> within the cytosol of mammalian cells, highlighting the dynamic interconversion of folate coenzymes and their roles in nucleotide synthesis and methylation. Key intermediates include tetrahydrofolate (THF)<\/b>, dihydrofolate (DHF)<\/b>, S-adenosylmethionine (S-AdoMet)<\/b>, S-adenosylhomocysteine (S-AdoHcy)<\/b>, and dimethylglycine (DMG)<\/b>. Enzymatic steps are catalyzed by: 1. Methionine synthase<\/i><\/u> (MS)<\/b>; 2. Betaine-homocysteine methyltransferase<\/i><\/u> (BHMT)<\/b>; 3. Methylenetetrahydrofolate reductase<\/i><\/u> (MTHFR)<\/b>; 4. Serine hydroxymethyltransferase<\/i><\/u> (SHMT)<\/b>; 5. Cystathionine \u03b2-synthase<\/i><\/u> (CBS)<\/b>.[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_id=”blog-scroll-point-3″][vc_column][vc_custom_heading text=”Folate\u2019s Protective Role in DNA Metabolism and Cancer Prevention” use_theme_fonts=”yes”][vc_column_text single_style=””]The foundational role of folate in DNA metabolism<\/b>\u2014both at the genetic<\/b> and epigenetic<\/b> levels\u2014serves as the logical entry point for understanding its potential to protect against cancer (see Figure 2<\/b>). Aberrations in DNA synthesis<\/b>, repair<\/b>, and methylation<\/b> are widely recognized as critical pathways<\/b> in carcinogenesis, and folate is intimately involved in all three. Given the diverse enzymatic functions<\/b> of folate derivatives, it is plausible that its protective effects arise from a convergence of multiple biochemical pathways<\/b>, rather than a single mechanism.<\/p>\n One of the most studied mechanisms involves uracil misincorporation<\/b> and its impact on genomic integrity<\/b> (see Figure 3<\/b>). Folate, specifically in the form of 5,10-methylenetetrahydrofolate (5,10-methylene THF)<\/b>, is essential for the conversion of uracil to thymidine<\/b>\u2014a key step in DNA synthesis. When folate availability is limited, the intracellular UTP\/TTP ratio<\/b> increases, leading to the erroneous incorporation of uracil into DNA<\/b>. This phenomenon has been consistently demonstrated in cell culture<\/b>, animal models<\/b>, and human studies<\/b> under conditions of severe folate deficiency<\/b>. However, it remains uncertain whether individuals with marginal folate status<\/b>\u2014common in the general population\u2014experience sufficient disruption in de novo thymidine synthesis<\/b> to cause significant uracil accumulation in DNA.<\/p>\n [\/vc_column_text][\/vc_column][\/vc_row][vc_row el_id=”blog-scroll-point-4″][vc_column][vc_custom_heading text=”Uracil-Induced DNA Damage and Modifying Nutritional Factors”][vc_column_text single_style=””]The susceptibility of tissues to uracil misincorporation is not governed by folate status alone. In rodent models, advanced age<\/b> was shown to increase the colon\u2019s vulnerability to uracil incorporation under folate-deficient conditions. Furthermore, vitamin B\u2081\u2082 deficiency<\/b>\u2014which induces a functional folate deficiency<\/b> via the methyl-folate trap<\/b>\u2014has been linked to elevated uracil levels in colonic DNA, even in the absence of overt folate depletion. In a human intervention study, individuals with low baseline plasma B\u2081\u2082 (<400 pg\/mL) <\/b>exhibited a blunted reduction in leukocyte uracil<\/b> following folic acid supplementation, underscoring the interdependence of B\u2081\u2082 and folate<\/b> in maintaining DNA integrity [3-4].<\/p>\n Interestingly, a mild depletion of all four one-carbon nutrients<\/b>\u2014B\u2082, B\u2086, B\u2081\u2082, and folate<\/b>\u2014did not significantly increase uracil misincorporation in the mouse colon, suggesting that threshold effects<\/b> or nutrient synergy<\/b> may modulate this response.<\/p>\n Under normal physiological conditions, low levels of uracil in DNA<\/b> are tolerated and efficiently repaired. However, when uracil incorporation becomes excessive, it triggers a cascade of genetic instability<\/b>. Mammalian cells deploy base excision repair (BER) systems<\/b> to remove uracil residues, a process that first creates an abasic site<\/b>, followed by a single-strand break<\/b> in the DNA backbone. When these breaks occur on opposite strands within ~<\/sup>14 base pairs<\/b>, they culminate in double-stranded breaks (DSBs)<\/b>\u2014a highly mutagenic event (see Figure 1<\/b> and Figure 3<\/b>).<\/p>\n DSBs are implicated in:<\/p>\n Animal studies have demonstrated that folate depletion<\/b> induces strand breaks in the coding regions of Apc and p53 genes<\/b>, accompanied by reduced mRNA expression<\/b> of these critical tumor suppressors. While causality between strand breaks and transcriptional repression remains to be definitively proven, the correlation is compelling. Notably, in cultured human lymphocytes, p53 strand breaks<\/b> did not consistently lead to reduced p53 mRNA<\/b>, suggesting that gene-specific repair dynamics<\/b> or compensatory transcriptional mechanisms<\/b> may influence outcomes.[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=”blog-text-35795″ el_id=”blog-scroll-point-5″][vc_column][vc_custom_heading text=”Genomic Vulnerability: Site-Specific DNA Damage Under Folate Stress” el_class=”blog-text-35795″][vc_column_text single_style=””]While folate deficiency\u2014and broader depletion of one-carbon nutrients<\/b>\u2014has been shown to induce genome-wide DNA strand breaks<\/b>, emerging evidence suggests that this damage is not uniformly distributed<\/b>. Instead, certain genomic regions<\/b> appear disproportionately vulnerable. Even within a single gene, strand break susceptibility<\/b> varies by locus. In rodent models, the colonic Apc and p53 genes<\/b> exhibited damage concentrated in highly conserved regions<\/b>\u2014the same regions most frequently mutated in human cancers.<\/p>\n Specifically:<\/p>\n Moreover, concurrent depletion<\/b> of folate, B\u2082, B\u2086, and B\u2081\u2082<\/b>\u2014even at subclinical levels<\/b>\u2014amplifies strand breakage beyond what is observed with folate deficiency alone. This synergistic effect underscores the interconnectedness of the one-carbon network<\/b> (see Figure 2<\/b>) and suggests that even mild inadequacies<\/b> can have compounding genomic consequences<\/b>.<\/p>\n One intuitive hypothesis is that site-specific uracil incorporation<\/b> may define a region\u2019s susceptibility to strand breaks. However, technological limitations<\/b> currently prevent accurate mapping of uracil incorporation at the nucleotide level, leaving this theory untested.[\/vc_column_text][vc_single_image image=”7096″ img_size=”full”][vc_column_text single_style=””]Figure 3. Uracil Repair Pathways in Mammalian Genomes: Compartmental Dynamics and Folate-Linked Vulnerabilities. <\/b>Illustration of the compartmentalized mechanisms<\/b> for repairing uracil residues<\/b> in mammalian DNA. Regions of DNA transiently exposed in single-stranded form<\/b> during replication<\/b> or transcription<\/b> are prone to hydrolytic deamination of cytosine<\/b>, generating U:G mismatches<\/b> (Pathway A<\/i><\/u><\/span>). These lesions are recognized and excised by SMUG1 uracil-DNA glycosylase<\/b>. If left unrepaired, they persist as U:A base pairs<\/b> in subsequent replication cycles, leading to C\u2192T transition mutations<\/b>. Separately, UNG uracil-DNA glycosylase<\/b> primarily targets U:A base pairs<\/b> that arise from the misincorporation of dUTP in place of TTP<\/b> during DNA synthesis\u2014a process exacerbated under folate-deficient conditions<\/b> (Pathway B<\/i><\/u><\/span>). Additional uracil glycosylases encoded by TDG<\/b> and MBD4<\/b> contribute to repair, though their specific roles remain less clearly defined<\/b>.[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=”blog-text-35795″ el_id=”blog-scroll-point-6″][vc_column][vc_custom_heading text=”Uracil Misincorporation: A Driver of Mutation and Structural Instability” el_class=”blog-text-35795″][vc_column_text single_style=””]Uracil incorporation into DNA can occur via two distinct mechanisms<\/b>, each with unique consequences (see Figure 3<\/b>):<\/p>\n Experimental folate deficiency in rodents has also been shown to impair excision repair<\/b> in colonic tissue, though whether this is due to excess uracil<\/b> or other metabolic disruptions remains unclear.<\/p>\n Collectively, these findings have positioned excessive uracil incorporation<\/b> as a central hypothesis<\/b> in explaining how inadequate folate status promotes carcinogenesis<\/b>. While aberrant DNA methylation<\/b> remains a plausible contributor, recent data suggest that defects in DNA synthesis and repair<\/b> may be even more critical.<\/p>\n In comparative studies of mouse strains:<\/p>\n Importantly, restoring methylation<\/b> in BALB\/C mice using trimethylglycine (betaine)<\/b> did not reduce tumorigenesis<\/b>, suggesting that nucleotide synthesis impairment<\/b>, not methylation loss, may be the dominant driver.<\/p>\n Further evidence comes from studies using rodents with gain- or loss-of-function mutations in cytosolic serine hydroxymethyltransferase (cSHMT)<\/b>\u2014a key enzyme that governs the partitioning of folate coenzymes<\/b> between methylation<\/b> and nucleotide synthesis<\/b>. Tumor susceptibility correlated with loss of coenzyme availability for nucleotide synthesis<\/b>, but not<\/b> with loss of methylation substrate. Intriguingly, folate depletion in colon cancer cells<\/b> can alter cSHMT expression<\/b>, introducing yet another mechanism by which folate imbalance may disrupt normal metabolic partitioning [5-6].[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=”blog-text-35795″ el_id=”blog-scroll-point-7″][vc_column][vc_custom_heading text=”Human Trials and Biomarkers of Chromosomal Damage” el_class=”blog-text-35795″][vc_column_text single_style=””]Human intervention trials have begun to clarify the conditions under which one-carbon vitamin supplementation<\/b> can mitigate uracil incorporation<\/b> and chromosomal instability<\/b>. The latter is often assessed using the micronucleus index<\/b>, a biomarker reflecting chromosomal breaks and losses<\/b> and considered a predictive marker of cancer risk<\/b>.<\/p>\n Key findings include:<\/p>\n [\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=”blog-text-35795″ el_id=”blog-scroll-point-8″][vc_column][vc_custom_heading text=”Next Steps: Methylation and Beyond” el_class=”blog-text-35795″][vc_column_text single_style=””]While uracil incorporation and DNA repair<\/b> have emerged as dominant mechanisms linking folate to carcinogenesis, other pathways\u2014particularly those involving biological methylation<\/b>\u2014remain critical and will be explored in depth in the next installment of this series. Cf. previous blogs entitled as: \u201cMTHFR at the Crossroads: Genetic Variants, Metabolic Disruption, and Clinical Consequences.<\/a>\u201d; \u201cCracking the Folate Code: How Enzymatic Polymorphisms Shape Health and Neurodevelopment.<\/a>\u201d)[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=”blog-text-35795″ el_id=”conclusion”][vc_column][vc_custom_heading text=”Summary and Conclusions” el_class=”blog-text-35795″][vc_column_text single_style=””]The intricate relationship between folate status and carcinogenesis<\/b> continues to unfold with both promise and complexity. Central to this narrative is the mechanism of uracil misincorporation into DNA<\/b>, a consequence of impaired thymidylate synthesis under conditions of folate deficiency. This biochemical disruption elevates the intracellular UTP\/TTP ratio<\/b>, leading to the erroneous incorporation of uracil in place of thymidine\u2014a process that triggers single- and double-stranded DNA breaks<\/b>, particularly within mutation-prone regions<\/b> of tumor suppressor genes such as Apc<\/i> and p53<\/i>. These strand breaks compromise genomic integrity, promote mutational events, and may suppress gene expression, thereby laying the groundwork for malignant transformation. The susceptibility to such damage is further amplified by subclinical deficiencies<\/b> in other one-carbon nutrients\u2014B\u2082, B\u2086, B\u2081\u2082, and choline<\/b>\u2014highlighting the synergistic nature of the one-carbon metabolic network.<\/p>\n Importantly, recent animal studies suggest that defects in nucleotide synthesis and repair<\/b> may play a more decisive role in tumorigenesis than disruptions in methylation alone. This insight challenges long-held assumptions and calls for a recalibration of mechanistic models. Moreover, emerging data from human intervention trials<\/b> reveal tissue-specific responses to folate supplementation, with colonic mucosa<\/b> showing resistance to uracil reduction despite systemic improvements\u2014underscoring the need for precision nutrition<\/b> and biomarker-guided strategies<\/b>.<\/p>\n Despite these advances, critical gaps remain<\/b>. The inability to accurately map site-specific uracil incorporation<\/b> limits our understanding of genomic vulnerability. The long-term consequences of high-dose folinic acid therapy<\/b>, particularly in pediatric populations with neurodevelopmental disorders<\/b>, remain insufficiently studied. As folate continues to be deployed therapeutically in diverse clinical contexts\u2014from cancer prevention to autism management\u2014there is an urgent need for longitudinal safety data<\/b>, mechanistic studies<\/b>, and population-specific risk assessments<\/b>.<\/p>\n In conclusion, folate\u2019s role in carcinogenesis is neither linear nor universal. It is a context-dependent modulator of cellular fate<\/b>, capable of both protecting and promoting depending on timing, dosage, and molecular milieu. Future research must embrace this complexity, integrating genetic background<\/b>, nutrient interactions<\/b>, and tissue-specific dynamics<\/b> to guide safe and effective interventions.<\/p>\n [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text single_style=”” el_class=”blog-banner-section”]<\/p>\n Folate (vitamin B9) is very important for your child\u2019s brain development!<\/p>\n During pregnancy, it helps prevent neural tube defects and plays a big role in forming a normal and healthy baby\u2019s brain and spinal cord. Folate also helps cells divide and assists in both DNA and RNA synthesis.<\/p>\n Emerging research suggests that the presence of FRAAs negatively impacts folate transport into the brain.<\/p>\n Yes, there is a test – The Folate Receptor Antibody Test (FRAT\u00ae<\/sup>) has emerged as a diagnostic tool for detecting the presence of FRAAs.<\/p>\n It is important to screen at an early age or as soon as possible as there may be corrective measures available. Please consult your physician for further information.<\/p>\n To request a test kit, click on the button below.<\/p>\n Request Now<\/a><\/div>\n<\/div>\n [\/vc_column_text][vc_column_text single_style=”” el_class=”text-gray-23″]For information on autism monitoring, screening and testing please read our blog<\/a>.[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_id=”blog-references” el_class=”blog-text-35795″][vc_column][vc_custom_heading text=”References” use_theme_fonts=”yes”][vc_column_text single_style=”” el_id=”blog-ref-3564″]<\/p>\n\n
\n<\/a><\/li>\n\n
\n
\n
\n
\n
\n
\n
\n[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=”blog-text-35795″ el_id=”blog-scroll-point-9″][vc_column][vc_custom_heading text=”Take-Home Messages” el_class=”blog-text-35795″][vc_column_text single_style=””]<\/p>\n\n
Did You Know? Folate Receptor Autoantibodies (FRAAs) may impede proper folate transport.<\/h4>\n
\n
Is there a test for identifying Folate Receptor Autoantibodies (FRAAs)?<\/h4>\n
![\"FRAT](\"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2023\/12\/frat-mascot-image.webp\")
<\/div>\n<\/div>\n\n
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/9096386\/<\/a>
\n\u2192 Demonstrates how folate deficiency leads to massive uracil incorporation and chromosomal breaks in human cells.<\/i><\/b><\/li>\n
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/20544289\/<\/a>
\n\u2192 Reviews folate\u2019s dual role in DNA stability and its context-dependent influence on colon cancer risk.<\/i><\/li>\n
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/11076664\/<\/a>
\n\u2192 Animal study showing increased uracil misincorporation and DNA strand breaks under moderate folate deficiency.<\/i><\/b><\/li>\n
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/14608107\/<\/a>
\n\u2192 Explores folate\u2019s protective and potentially tumor-promoting effects depending on timing and dose.<\/i><\/b><\/li>\n
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/18644786\/<\/a>
\n\u2192 Highlights that mitochondrial SHMT-derived one-carbon units are essential for folate-mediated one-carbon metabolism in the cytoplasm.<\/i><\/b><\/li>\n